1Choussat R,Montalescot G,Collet JP,Vicaut E,Ankri A,Gallois V,et al.A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention[].Journal of the American College of Cardiology.2002
2Goodman SG,Cohen M,Bigonzi F,Gurfinkel EP,Radley DR,Le Iouer V,et al.Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparion for unstable coronary artery disease:one-year results of the ESSENCE study.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave CORONARY Events[].Journal of the American College of Cardiology.2000
3Cohen M,Demers C,Gurfinkel EP,Turpie AG,Fromell GJ,Goodman S,et al.A comparison of low-molecular- weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group[].The New England Journal of Medicine.1997
4Montalescot G,Collet JP,Tanguy ML,Ankri A,Payot L,Dumaine R,et al.Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin[].Circulation.2004
5Argenti D,Hoppensteadt D,Heald D,Jensen B,Fareed J.Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy[].American Journal of Therapeutics.2003
6Martin JL,Fry ET,Sanderink GJ,Atherley TH,Guimart CM,Chevalier PJ,et al.Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study[].Catheterization and Cardiovascular Interventions.2004
7Moliterno DJ,Hermiller JB,Kereiakes DJ,Yow E,Applegate RJ,Braden GA,et al.A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention.Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study[].Journal of the American College of Cardiology.2003
8Kereiakes DJ,Montalescot G,Antman EM,Cohen M,Darius H,Ferguson JJ,et al.Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus[].American Heart Journal.2002
9Collet JP,Montalescot G,Golmard JL,Tanguy ML,Ankri A,Choussat R,et al.Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes[].American Heart Journal.2004
10Ferguson JJ,Califf RM,Antman EM,Cohen M,Grines CL,Goodman S,et al.SYNERGY Trial Investigators.Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial[].The Journal of The American Medical Association.2004
